Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMABusiness Wire • 06/26/26
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?The Motley Fool • 06/22/26
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?The Motley Fool • 06/20/26
Bears are Losing Control Over Omeros (OMER), Here's Why It's a 'Buy' NowZacks Investment Research • 06/04/26
Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026Business Wire • 05/11/26
Wall Street Analysts Believe Omeros (OMER) Could Rally 222.76%: Here's is How to TradeZacks Investment Research • 04/27/26
Does Omeros (OMER) Have the Potential to Rally 266.67% as Wall Street Analysts Expect?Zacks Investment Research • 04/10/26
Omeros: Making The Bull Case On Q4 Earnings, Ahead Of Key Q1 Commercial UpdatesSeeking Alpha • 04/02/26
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial ResultsBusiness Wire • 03/31/26
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026Business Wire • 03/26/26
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA TreatmentBusiness Wire • 03/21/26
Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment TranscriptSeeking Alpha • 01/08/26
Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMAZacks Investment Research • 12/29/25